Regenerative Medicine Examples: 12 Real Cases to Know in 2026
Introduction: Why “Regenerative Medicine Examples” Needs a Trust-First List
This article provides a single, skimmable list of 12 verifiable, named regenerative medicine examples, focusing on specific drugs, procedures, patients, and landmark cases rather than a vague overview of the science.
Regenerative medicine refers to therapies that repair, replace, or regenerate damaged cells, tissues, or organs rather than simply treating symptoms.
Most roundups on this topic share one problem: they place FDA-approved treatments next to experimental or clinic-marketed ones without telling readers which is which. A lab-grown bladder from a pioneering 1999 trial, a celebrity knee injection, and a fully approved gene therapy often appear side by side as if they had equal standing. They do not.
The examples below fall into four categories:
- Stem cell therapies
- PRP (platelet-rich plasma)
- Tissue engineering
- Gene and cell therapy
This is not fringe science. The global regenerative medicine market is estimated at roughly $48 to $54 billion in 2026, depending on the research firm’s methodology. The field is moving quickly, so clarity matters.
The transparency promise: every example below is explicitly tagged as FDA-approved, RMAT-designated, or investigational.
How to Read This List: FDA-Approved vs. RMAT-Designated vs. Investigational
Three labels appear throughout this article:
- FDA-approved: The U.S. Food and Drug Administration has granted full marketing approval for a specific indication. Approval applies only to that use, not to every condition a clinic might advertise.
- RMAT-designated: The Regenerative Medicine Advanced Therapy designation, created under the 21st Century Cures Act of 2016, is an expedited development pathway. It offers closer FDA guidance and potentially faster review. It is not an approval.
- Investigational: The therapy is being studied in clinical trials, used in pioneering or compassionate cases, or offered without FDA approval for the advertised purpose.
Full approval remains rare. As of September 2025, the RMAT program had received nearly 370 requests, granted 184 designations, and produced only 13 full marketing approvals.
The 351 vs. 361 Distinction
The FDA also sorts cell and tissue products into two regulatory tracks, named after sections of the Public Health Service Act:
| Track | What It Means | Examples |
|---|---|---|
| 351 products | Require full premarket approval, with clinical evidence of safety and efficacy | CAR-T therapies, Ryoncil |
| 361 products | Minimally manipulated tissues intended for homologous use; no premarket approval required | Many PRP and birth-tissue products |
This distinction is rarely explained to consumers, yet it is the most practical fact for evaluating any clinic’s regenerative medicine claims. A 361 product can be legally offered without the clinical trial evidence that a 351 product must provide.
The same framework applies to every example below.
Category 1: Stem Cell Therapy Examples
Stem cells can develop into many different cell types, which makes them central to regenerative medicine. As of 2026, however, only a narrow set of stem cell applications is FDA-approved. Most others remain investigational.
The research pipeline is large. More than 5,000 registered clinical trials on ClinicalTrials.gov test stem cell therapies across organs including the lung, kidney, heart, and liver. Readers who want mechanism-level detail can consult the dedicated stem cell therapy guide on this site.
Example 1: Hematopoietic (Cord Blood) Stem Cell Transplants
Tag: FDA-approved
Blood-forming (hematopoietic) stem cells derived from umbilical cord blood are the only stem cell products with full, longstanding FDA approval in the United States. They are used to treat blood cancers and blood disorders such as leukemia and certain inherited conditions, including sickle cell disease, by rebuilding a patient’s blood and immune system.
Hematopoietic transplantation is the regenerative medicine “gold standard” precedent. Newer cell therapies are measured against it.
Key contrast: most orthopedic, anti-aging, and cosmetic stem cell offerings promoted by clinics are not in this approved category.
Example 2: Ryoncil (Remestemcel-L) for Pediatric GvHD
Tag: FDA-approved (December 2024)
Ryoncil is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Its indication is specific: pediatric steroid-refractory graft-versus-host disease (GvHD), a serious complication that can follow bone marrow transplantation when donor immune cells attack the recipient’s body.
Researchers have studied MSCs for decades, and no MSC product had received full U.S. approval before Ryoncil. That makes it a milestone for the field.
The approval is narrow. It covers one pediatric condition. It does not validate MSC injections marketed for knees, backs, skin, or longevity.
Example 3: Investigational Orthopedic and Anti-Aging Stem Cell Treatments
Tag: Investigational / largely unapproved
Most stem cell injections marketed for joints, aesthetics, or general wellness fall outside FDA-approved use. Many are offered under the 361 regulatory track as minimally manipulated tissue products. Because 361 products do not require premarket approval, they can be legally offered without proof of efficacy for the conditions advertised.
Promising research is under way. A 2025 landscape analysis identified 115 regulatory-approved clinical trials testing 83 human pluripotent stem cell (hPSC)-derived products. More than 1,200 patients had been dosed, with no generalizable safety signal identified to date. That is encouraging research, but it is not approval.
Questions patients can ask any clinic:
- Is this product classified as 351 or 361?
- Does it have FDA approval for this specific condition?
- Is this treatment part of a registered clinical trial?
Category 2: PRP (Platelet-Rich Plasma) Examples
PRP uses a patient’s own blood, which is spun in a centrifuge to concentrate platelets. The result is injected into injured tendons, ligaments, or joints. PRP is autologous (from the patient) and cell-free in the sense that it contains no stem cells. Its goal is to deliver growth factors that support the body’s healing response.
Regulatory status: PRP is not FDA-approved as a cure for any disease. It is typically regulated as a 361 product rather than as a drug.
PRP is also the most publicly visible regenerative technique, largely because elite athletes have used it, even though its curative value remains unproven. Readers interested in procedure details and candidacy can review the PRP guide on this site.
Example 4: Tiger Woods and PRP for Knee and Back Injuries
Tag: Investigational / supportive therapy
Tiger Woods is one of the most frequently cited examples in sports medicine coverage of PRP. He reportedly received PRP injections during recovery from his long history of knee and back injuries.
His case shows how PRP is typically used in clinical practice. It is injected directly into injured tendon or joint tissue to stimulate the body’s own repair processes, usually alongside surgery, rehabilitation, and physical therapy. It functions as an adjunct to recovery, not as a standalone cure.
Example 5: Rafael Nadal’s PRP Treatments for Knee Tendinopathy
Tag: Investigational / supportive therapy
Rafael Nadal’s chronic knee tendinopathy is well documented. He reportedly used PRP treatments over the years to manage persistent tendon pain while competing at the highest level.
His case illustrates PRP’s typical real-world role: symptom management and recovery support for elite performers. It does not show that PRP structurally cures damaged tissue.
Example 6: Kobe Bryant, Alex Rodriguez, and the PRP Media Boom
Tag: Investigational / supportive therapy
Kobe Bryant and Alex Rodriguez also reportedly used PRP and related blood-based treatments for joint and injury recovery. Their high-profile use helped bring the technique into mainstream sports media.
Journalistic coverage, including reporting from CBC News, has described the sports hype around PRP as “a powerful marketing tool” that can distort the underlying science.
Caution: celebrity use does not equal FDA endorsement. Professional athletes often receive many treatments at once, so it is difficult to attribute their recoveries to PRP alone. Their outcomes are not guaranteed for the general public.
Category 3: Tissue Engineering Examples
Tissue engineering combines living cells, biomaterials, and supportive scaffolds to grow replacement tissues or organs, often starting in the laboratory. The field’s history runs from early cultured skin grafts and lab-grown bladders to the current frontier of 3D bioprinting. Readers seeking more technical depth can explore the tissue engineering guide on this site.
Example 7: MACI, FDA-Approved Cartilage Repair
Tag: FDA-approved
MACI (Matrix-induced Autologous Chondrocyte Implantation), developed by Vericel, repairs cartilage defects in the knee. The process has three steps:
- A small sample of the patient’s healthy cartilage cells is harvested.
- The cells are expanded in a laboratory.
- The cells are seeded onto a collagen matrix and implanted into the damaged area.
Published data report an 80 to 90% success rate for knee cartilage repair. That makes MACI one of the most consistently successful tissue-engineered products in clinical use.
Example 8: Wake Forest’s Lab-Grown Bladders
Tag: Landmark clinical case (pioneering use, not a mass-market approved product)
In 1999, a team led by Dr. Anthony Atala at Wake Forest implanted lab-grown bladders into seven children with spina bifida. The results were reported in 2006. The bladders were built from each patient’s own cells grown on a biodegradable scaffold.
This was one of the earliest “whole organ” tissue-engineering achievements, and it laid the groundwork for later organ-regeneration research.
The next milestone came in 2008, when Martin Birchall’s team in the United Kingdom transplanted a tissue-engineered trachea. It was created by seeding a donor scaffold with the patient’s own stem cells and became the first organ generated specifically from a patient’s own stem cells.
Example 9: Epicel and the Frontier of 3D Bioprinting
Tag: FDA-approved (Epicel); Investigational / preclinical (bioprinting)
Epicel grew out of cultured skin-cell research that began in 1979 and is one of the earliest tissue-engineered products used in clinical care. It consists of sheets of skin cells grown from a patient’s own cells. These sheets cover large areas of severe, life-threatening burns when not enough healthy skin is available for conventional grafts.
At the other end of the timeline is 3D bioprinting, in which cells and biomaterials are deposited layer by layer to build tissue structures. Current work includes:
- Bioprinted cardiac patches made from induced pluripotent stem cells (iPSCs)
- 3D-printed minichannel tracheal and cartilage grafts
Both remain in preclinical models. Together, Epicel and bioprinting show how far the field has come, from 1970s skin cultures to engineered tissue in 2026 research laboratories.
Category 4: Gene and Cell Therapy Examples
Gene and cell therapies introduce or alter genetic material, or engineer a patient’s own cells, to treat disease at its root cause. As of early 2026, the FDA has approved more than 30 cell and gene therapy products in the U.S. Stem cell-based therapies are the fastest-growing subcategory. The cell and gene therapy guide on this site covers mechanisms and eligibility in more detail.
Example 10: Zolgensma for Spinal Muscular Atrophy
Tag: FDA-approved
Zolgensma (onasemnogene abeparvovec) is a one-time gene therapy for spinal muscular atrophy (SMA), a genetic disease that destroys motor neurons and causes progressive muscle weakness in infants and young children. It delivers a functional copy of the missing gene.
Zolgensma is the top-selling gene therapy worldwide, with roughly $1.23 billion in 2025 sales, which reflects both its clinical impact and its high profile.
Its predecessor in the approval timeline was Luxturna, approved in 2017. Luxturna was the first FDA-approved gene therapy for an inherited disease, targeting retinal dystrophy caused by RPE65 gene mutations.
Example 11: Casgevy, the First CRISPR Gene-Editing Therapy
Tag: FDA-approved (December 2023)
Casgevy (exagamglogene autotemcel) is the first CRISPR-Cas9 gene-editing therapy approved in the United States. It is indicated for:
- Sickle cell disease
- Transfusion-dependent beta-thalassemia
Earlier gene therapies such as Zolgensma add a working gene. Casgevy instead edits the patient’s own cells directly. Its approval moved precision gene editing from a research concept to an approved clinical treatment.
Example 12: Kymriah and CAR-T Cell Therapy for Cancer
Tag: FDA-approved
Kymriah was among the first approved CAR-T therapies. Others in the class include Yescarta, Carvykti, Abecma, and Tecartus. The process works in three steps:
- A patient’s own T cells (immune cells) are extracted.
- The cells are genetically engineered to recognize specific cancer cells.
- The modified cells are infused back into the patient to attack the cancer.
In advanced follicular lymphoma trials, CAR-T therapy eliminated cancer in nearly 80% of patients.
CAR-T combines cell therapy and genetic engineering, two of the main approaches in modern regenerative medicine.
At-a-Glance: All 12 Regenerative Medicine Examples and Their Regulatory Status
| # | Example | Category | Status |
|---|---|---|---|
| 1 | Hematopoietic (cord blood) stem cell transplants | Stem cell | FDA-approved |
| 2 | Ryoncil (remestemcel-L) for pediatric GvHD | Stem cell | FDA-approved (Dec. 2024) |
| 3 | Orthopedic and anti-aging stem cell treatments | Stem cell | Investigational / largely unapproved |
| 4 | Tiger Woods: PRP for knee and back | PRP | Investigational / supportive |
| 5 | Rafael Nadal: PRP for knee tendinopathy | PRP | Investigational / supportive |
| 6 | Kobe Bryant and Alex Rodriguez: PRP media boom | PRP | Investigational / supportive |
| 7 | MACI cartilage repair | Tissue engineering | FDA-approved |
| 8 | Wake Forest lab-grown bladders | Tissue engineering | Landmark pioneering case |
| 9 | Epicel / 3D bioprinting | Tissue engineering | FDA-approved / Preclinical |
| 10 | Zolgensma for SMA | Gene therapy | FDA-approved |
| 11 | Casgevy (CRISPR) | Gene editing | FDA-approved (Dec. 2023) |
| 12 | Kymriah and CAR-T therapies | Cell and gene therapy | FDA-approved |
Unlike much clinic-marketing content, this list states each entry’s regulatory status plainly. None of the examples on this list currently holds RMAT designation as its primary status. Many therapies in the pipeline do, which is why the label still matters when evaluating new claims.
The Bigger Picture: Market Growth and Where Regenerative Medicine Is Headed
Market estimates vary considerably, so a range is more informative than a single figure:
- Grand View Research: $48.3 billion in 2026, growing to $90 billion by 2030 (16.8% CAGR)
- Precedence Research: $53.65 billion in 2026, growing to $234.85 billion by 2035
The spread comes from differences in methodology, such as which product types are included, how regions are weighted, and what growth assumptions are used. All of the estimates point to substantial growth.
Clinical progress points the same way. More than 30 FDA-approved cell and gene therapies now exist, and stem cell-based approaches are the fastest-growing subcategory. With 184 RMAT designations producing 13 full approvals as of September 2025, more approvals are likely in the coming years.
Growth in investigational research does not mean a therapy is approved today. That distinction remains the key filter for evaluating new regenerative medicine claims.
Conclusion: What These 12 Examples Reveal About Regenerative Medicine in 2026
Across stem cells, PRP, tissue engineering, and gene and cell therapy, regenerative medicine covers a wide range of evidence levels:
- Fully FDA-approved treatments: Zolgensma, Casgevy, Kymriah, MACI, Ryoncil, Epicel, and cord blood transplants
- Widely used but not approved as cures: PRP
- Pioneering investigational frontiers: lab-grown organs and 3D bioprinting
Knowing whether a therapy is FDA-approved, RMAT-designated, or investigational is the most important filter for evaluating any regenerative treatment claim. Asking whether a product falls under the 351 or 361 track is a close second.
The field has moved from a single approved stem cell category decades ago to more than 30 approved cell and gene therapies today, so more real-world examples are likely to join this list soon. Readers can use this list as a reference before researching or discussing any specific treatment.
Next Steps: Explore Each Regenerative Medicine Category in Depth
Each category has a dedicated guide on this site with more detail:
- Stem Cell Therapy Guide: Ryoncil, cord blood transplants, and the evidence behind investigational MSC treatments.
- PRP Guide: procedure details, candidacy, and realistic expectations beyond celebrity headlines.
- Tissue Engineering Guide: MACI, lab-grown organs, and bioprinting developments.
- Cell and Gene Therapy Guide: how CAR-T, CRISPR editing, and gene-replacement therapies work.
Anyone considering a regenerative treatment should consult a qualified medical professional. That conversation should confirm the treatment’s FDA status for the specific condition and whether the treatment is the right fit.
